If Congress doesn’t act soon, CMS’s flexible funding of telemedicine visits—a temporary holdover from the COVID era—will dry up next year. A new study may help persuade fiscally cautious representatives not to let that happen.
In a survey, employers told the Business Group on Health that they aren’t yet seeing evidence of long-term health benefits from taking GLP-1s for weight loss, leaving them unsure how to manage costs while continuing to cover them.
